News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The company’s shares closed yesterday at $686.33.

What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...

A lawsuit filed by three former employees of Bellflower St. John Bosco High alleges that highly decorated football coach Jason Negro embezzled money from the Catholic school for years and had ...

In 1889, Vincent van Gogh committed himself to a psychiatric asylum in Southern France, where he spent a turbulent year creating roughly 150 paintings, including masterpieces such as “Irises ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron Science Talent Search. Melody Hong of MacArthur High School in Levittown ...